Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 10% Improvement Relative Risk Boye et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 9,531 patients in the USA Lower hospitalization with metformin (p=0.0000028) Boye et al., Diabetes Therapy, doi:10.1007/s13300-021-01110-1 Favors metformin Favors control
Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States
Boye et al., Diabetes Therapy, doi:10.1007/s13300-021-01110-1
Boye et al., Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among.., Diabetes Therapy, doi:10.1007/s13300-021-01110-1
Jul 2021   Source   PDF  
  All Studies   Meta
Retrospective 9531 COVID+ diabetes patients in the USA, showing lower risk of hospitalization with existing biguanides treatment (defined as mainly metformin in the abstract and entirely metformin in the text).
risk of hospitalization, 10.0% lower, RR 0.90, p < 0.001, treatment 2,067 of 4,250 (48.6%), control 3,196 of 5,281 (60.5%), NNT 8.4, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Boye et al., 18 Jul 2021, retrospective, USA, peer-reviewed, 14 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Diabetes Ther (2021) 12:2223–2239 ORIGINAL RESEARCH Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States Kristina S. Boye . Elif Tokar Erdemir . Nathan Zimmerman . Abraham Reddy . Brian D. Benneyworth . Matan C. Dabora . Emily R. Hankosky . M. Angelyn Bethel . Callahan Clark . Cody J. Lensing . Scott Sailer . Ramira San Juan . Robert J. Heine . Lida Etemad Received: April 28, 2021 / Accepted: June 28, 2021 / Published online: July 18, 2021 Ó The Author(s) 2021 ABSTRACT Introduction: Diabetes has been identified as a high-risk comorbidity for COVID-19 hospitalization. We evaluated additional risk factors for COVID-19 hospitalization and in-hospital mortality in a nationwide US database. Methods: This retrospective study utilized the UnitedHealth Group Clinical Discovery Database (January 1, 2019–July 15, 2020) containing de-identified nationwide administrative claims, SARS-CoV-2 laboratory test results, and COVID19 inpatient admissions data. Logistic regression was used to understand risk factors for hospitalization and in-hospital mortality among people with type 2 diabetes (T2D) and in the overall population. Robustness of associations was further confirmed by subgroup and sensitivity analyses in the T2D population. Supplementary Information The online version contains supplementary material available at https:// K. S. Boye  B. D. Benneyworth  M. C. Dabora  E. R. Hankosky  M. A. Bethel  R. J. Heine Eli Lilly and Company, Indianapolis, IN, USA E. Tokar Erdemir (&)  N. Zimmerman  A. Reddy  C. Clark  C. J. Lensing  S. Sailer  R. San Juan  L. Etemad OptumLabs at UnitedHealth Group, Minneapolis, MN, USA e-mail: Results: A total of 36,364 people were identified who were either SARS-CoV-2? or hospitalized for COVID-19. T2D was associated with increased COVID-19-related hospitalization and mortality. Factors associated with increased hospitalization risk were largely consistent in the overall population and the T2D subgroup, including age, male sex, and these top five comorbidities: dementia, metastatic tumor, congestive heart failure, paraplegia, and metabolic disease. Biguanides (mainly metformin) were consistently associated with lower odds of hospitalization, whereas sulfonylureas and insulins were associated with greater odds of hospitalization among people with T2D. Conclusion: In this nationwide US analysis, T2D was identified as an independent risk factor for COVID-19 complications. Many factors conferred similar risk of hospitalization across both populations; however, particular diabetes medications may be markers for differential risk. The insights on comorbidities and medications may inform population health initiatives, including prevention efforts for high-risk patient populations such as those with T2D. Keywords: Claim-based analysis; COVID-19; Risk factors; SARS-CoV-2; Type 2 diabetes 2224 Key Summary Points Why carry out this study? The clinical and demographic characteristics as well as specific risk factors of patients with diabetes with severe forms of COVID-19 in the US have not been extensively studied. This study aimed to characterize additional risk factors for COVID-19 hospitalization and in-hospital mortality among those with type 2 diabetes mellitus (T2DM) and the overall population in..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop